Hassan Lemjabbar-Alaoui, Ph.D.
- Professor of Surgery
- Division of Adult Cardiothoracic Surgery
Contact Information
University of California, San Francisco
San Francisco, CA 94143-1724
415-476-9303 Phone
[email protected]
Education
University of Paris VII, B.S., Biology, 1988-1989
University of Paris VII, M.S., Molecular Biology and Immunology, 1989-1991
University of Paris VI, M.S., Biochemistry, 1991-1992
University of Paris VI, Post-Master University Diploma (DU), Clinical Pharmacokinetics and Therapeutics, 1992-1993
University of Paris XIII, Post-Master DE.A of Science, Medical and Biological Engineering, 1993-1994
University of Paris XII, Ph.D., Molecular and Cell Biology, 1994-1997
Biography
Hassan Lemjabbar-Alaoui, Ph.D. is a biomedical scientist and Principal Investigator in the Thoracic Oncology Laboratory. Dr. Alaoui received his Ph.D. from the University of Paris XII. Since receiving his Ph.D. from the University of Paris XII, he has focused his research work on deciphering the molecular mechanisms of lung cancer and other thoracic malignancies, and discovering novel targeted therapies and diagnostic biomarkers with clinical utility for the treatment of these diseases. Dr. Alaoui began these studies in 1997 as a postdoctoral fellow/Assistant Research Anatomist in Dr. Carol Basbaum's lab at UCSF, and continued them as an Assistant Professor of Anatomy at UCSF.
Dr. Alaoui has also been the recipient of numerous awards including the prestigious National Institutes of Health/(NIH-NCI)/ U01 grant, the Doctors Cancer Foundation award, the Pfizer-CTI Research Program award, and the American Cancer Society.
Research Overview
Dr. Alaoui's research is focused on elucidating diagnostic biomarkers and developing novel targeted therapies for treatment of lung cancer, mesothelioma and esophageal cancer. My lab seeks to gain a keen understanding of the molecular mechanisms underlying these diseases. Our projects include:
- Investigating the role of extracellular heparan sulfate degrading sulfatases (SULFs) in tumorigenesis, and finding novel ways to target them.
- Discovering novel blood biomarkers for early detection and stratification of thoracic malignancies.
- Elucidating the molecular mechanisms of multi-drug resistance in thoracic malignancies.
- Developing DNA repair inhibitors for thoracic malignancies, particularly small-molecule inhibitors, which hold great promise for damaging tumor cells.
- Adapting cAbl inhibitors, FDA-approved for the treatment of chronic myeloid leukemia (CML), for treatment of malignant mesothelioma, a devastating and currently incurable disease.
Research & Funding
- Extracellular Sulfatases As Novel Biomarkers For Early Detection of CancerSponsor: NIH/NCISponsor ID: U01CA168878Funding Period:Aug 2012-Jun 2017Principal Investigator
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 30
- Yang YW, Jablons DM, Lemjabbar-Alaoui H. Extracellular sulfatases as potential blood-based biomarkers for early detection of lung cancer. Exp Lung Res. 2021 May-Aug; 47(6):261-279. View in PubMed
- Luo X, Campbell NA, He L, O'Brien DR, Singer MS, Lemjabbar-Alaoui H, Ahn KS, Smoot R, Torbenson MS, Rosen SD, Roberts LR. Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis. Hepatology. 2021 09; 74(3):1411-1428. View in PubMed
- Yang YW, Phillips JJ, Jablons DM, Lemjabbar-Alaoui H. Development of novel monoclonal antibodies and immunoassays for sensitive and specific detection of SULF1 endosulfatase. Biochim Biophys Acta Gen Subj. 2021 02; 1865(2):129802. View in PubMed
- Yang YW, Marrufo A, Chase J, Woodard GA, Jablons DM, Lemjabbar-Alaoui H. Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma. Exp Lung Res. 2021 02; 47(1):9-25. View in PubMed
- Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020; 10(8):2649-2676. View in PubMed
- View All Publications
In the News
- UCSF Thoracic Oncology Program - August 27, 2012The NIH has awarded two UCF scientists, Hassan Lemjabbar-Alaoui, Ph.D and Joanna J. Phillips, M.D., Ph.D., a five-year $2.2m grant to study the clinical utility of extracellular heparan sulfate endosulfatases, or SULFs, as biomarkers for early detection of non-small cell lung cancer (NSCLC) and malignant astrocytoma. Lung cancer is the leading cause of cancer death in the U.S. and world-wide. Astrocytomas are primary brain neoplasms (tumors). Glioblastoma multiforme (GBM), the most common and [...]
- UCSF Thoracic Oncology Program - January 09, 2012A team consisting of Hassan Lemjabbar-Alaoui, Ph.D., Assistant Adjunct Professor of Surgery and principal Investigator in the Thoracic Oncology Laboratory and Alaoui Lab, and Steven Rosen, PhD, Professor and Vice-chair of the Department of Anatomy, are developing a novel treatment for lung cancer in a unique collaboration between UCSF and Pfizer, the world's largest drug company. The Rosen-Alaoui team has identified an enzyme found at high levels in lung and other cancers and is developing [...]